Study to Compare the Bioavailability, Safety and Tolerability of XM17 in Healthy, Down Regulated Young Women
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
Aim of this study is to demonstrate the bioequivalence of single subcutaneous doses of XM17
and Gonal-f® in a confirmatory design. Furthermore, safety and tolerability will be assessed
in human healthy female subjects. Only female subjects will be included in the study to reach
the objectives of the study.